Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

被引:130
|
作者
del Alcazar, Carlos Rodrigo Gil [1 ]
Hardebeck, Molly Catherine [1 ]
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Gao, Xiaohuan [1 ]
Yan, Jingsheng [2 ]
Xie, Xian-Jin [2 ]
Bachoo, Robert [3 ]
Li, Li [3 ,4 ]
Habib, Amyn A. [3 ,4 ]
Burma, Sandeep [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金
美国国家航空航天局;
关键词
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; DEPENDENT PROTEIN-KINASE; RAPAMYCIN INHIBITOR; PRECLINICAL EVALUATION; ADJUVANT TEMOZOLOMIDE; DAMAGE RESPONSE; CANCER-CELLS; IN-VIVO; ATM; RADIOTHERAPY;
D O I
10.1158/1078-0432.CCR-13-1607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文
共 50 条
  • [31] Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models
    Uestuen, Sevdican
    Lassnig, Caroline
    Preitschopf, Andrea
    Mikula, Mario
    Mueller, Mathias
    Hengstschlaeger, Markus
    Weichhart, Thomas
    TRANSPLANT IMMUNOLOGY, 2015, 33 (01) : 45 - 50
  • [32] Effect of the combination of the dual mTOR/pI3K inhibitor NVP-BEZ235 with gemcitabine on growth inhibition in pancreatic cancer cells in vitro and in vivo
    Maute, Luise
    Wicht, Johannes
    Zoernig, Martin
    Niederhagen, Manuel
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells
    Udawant, Shreya
    Litif, Carl
    Lopez, Alma
    Gunn, Bonnie
    Schuenzel, Erin
    Keniry, Megan
    CELLS, 2021, 10 (11)
  • [34] Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor
    Shehata, Medhat
    Schnabl, Susanne
    Demirtas, Dita
    Tauber, Stefanie
    Hilgarth, Martin
    Bilban, Martin
    Vanura, Katrina
    Porpaczy, Edit
    Fonatsch, Christa
    Stilgenbauer, Stephan
    Schwarzmeier, Josef D.
    Hubmann, Rainer
    Gaiger, Alexander
    Zielinski, Christoph
    Maira, Sauveur-Michel
    Garcia-Echeverria, Carlos
    Hackl, Wolfgang
    Jaeger, Ulrich
    BLOOD, 2008, 112 (11) : 1086 - 1086
  • [35] Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
    Yu, Hao
    Shi, Ni
    Pan, Zui
    Chen, Tong
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells
    Ji Yinghua
    Di Wenyu
    Yang Qinghui
    Lu Zhihong
    Cai Weimei
    Wu Jieqing
    CLINICAL LABORATORY, 2015, 61 (08) : 1043 - 1051
  • [37] NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
    Moon, Du G.
    Lee, Sang E.
    Oh, Mi M.
    Lee, Sang C.
    Jeong, Seong J.
    Hong, Sung K.
    Yoon, Cheol Y.
    Byun, Seok S.
    Park, Hong S.
    Cheon, Jun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (03) : 1027 - 1035
  • [38] Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining
    Schoetz, Ulrike
    Balzer, Viola
    Brandt, Friedrich-Wilhelm
    Ziemann, Frank
    Subtil, Florentine S. B.
    Rieckmann, Thorsten
    Koecher, Sabrina
    Engenhart-Cabillic, Rita
    Dikomey, Ekkehard
    Wittig, Andrea
    Arenz, Andrea
    CANCERS, 2020, 12 (02)
  • [39] The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer
    Awasthi, Niranjan
    Yen, Peter L.
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (03) : 784 - 791
  • [40] Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
    Li, Jie
    Wang, Xiaozi
    Ma, Chuanbao
    Xu, Shasha
    Xu, Mengyao
    Yang, Jie
    Wang, Ruicang
    Xue, Liying
    MOLECULAR MEDICINE REPORTS, 2021, 23 (04)